TABLE 1
FROM:
Pharmacogenetic Analysis of Genes Implicated in Rodent Models of Antidepressant Response: Association of TREK1 and Treatment Resistance in the STAR*D Study
Roy H Perlis, Priya Moorjani, Jesen Fagerness, Shaun Purcell, Madhukar H Trivedi, Maurizio Fava, A John Rush and Jordan W Smoller
BACK TO ARTICLETable 1. Clinical and Sociodemographic Features of Cohorts Used for Analyses of Level 1, 2, and 3 Outcomes
| Level 1 | Level 2a | Level 3 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| n | Mean/% | SD | n | Mean/% | SD | n | Mean/% | SD | |
| N | 1554 | 751 | 225 | ||||||
| Sex | |||||||||
| Female | 960 | 62% | 443 | 59% | 116 | 52% | |||
| Race | |||||||||
| Caucasian | 1209 | 78% | 599 | 80% | 182 | 81% | |||
| Age at study entry (years) | 1554 | 42.7 | 13.1 | 751 | 42.9 | 12.8 | 225 | 45.0 | 12.2 |
| Age at illness onset (years) | 1540 | 25.8 | 14.7 | 743 | 25.3 | 14.4 | 223 | 26.3 | 14.4 |
| Episode length (months) | 1544 | 24.7 | 54.1 | 746 | 28.3 | 62.3 | 223 | 27.8 | 62.3 |
| HAM-D-17 at study entry | 1451 | 21.7 | 5.2 | 701 | 22.4 | 5.2 | 208 | 23.6 | 5.1 |
| QIDS-C16 at study entry | 1550 | 16.8 | 3.3 | 749 | 17.2 | 3.2 | 225 | 17.7 | 3.1 |
| QIDS-C16 at level entry | 1550 | 16.8 | 3.3 | 751 | 12.7 | 4.2 | 225 | 13.6 | 4.0 |
| Remission | 565 | 36% | 264 | 35% | 40 | 18% | |||
Summary of clinical and sociodemographic features for the genetics cohort as a whole (level 1), and the subsets used for the level 2 and 3 analyses.
a Excluding individuals randomized to cognitive therapy.